FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics faces market volatility and legal investigations following the release of FDA staff documents regarding its therapy, Deramiocel.
The reporting (5)
- CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor T The National Law Review · 18h ago
- CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ Yahoo Finance · 18h ago
- CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC GlobeNewswire · 18h ago
- Biotech Stocks Facing FDA Decision In August 2026 RTTNews · 18h ago
- BREAKING: Capricor Therapeutics Investigated for Securities GlobeNewswire · 18h ago
The brief
Capricor Therapeutics is experiencing significant stock price declines following the release of FDA documents that raised concerns regarding data for the therapy Deramiocel. The company is now the subject of investigations by multiple law firms, including Kehoe Law Firm, P.C. and Holzer & Holzer, LLC, focused on potential securities issues.
Coverage from Yahoo Finance, RTTNews, and the National Law Review emphasizes the stark divergence in analyst outlooks regarding the probability of regulatory approval for Deramiocel. Documents released by the FDA have been characterized by market observers as negative, contributing to the stock's performance decline.
Attention remains on the upcoming regulatory timeline for biotech firms, with an FDA decision regarding the company's therapy scheduled for August 2026. Coverage does not yet specify how the ongoing legal investigations will impact the firm's regulatory strategy or corporate governance.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What is the primary cause of the current market activity for Capricor?
Market activity follows the release of FDA staff documents that expressed concerns regarding data for the therapy Deramiocel.
Are there active investigations into the company?
Yes, law firms including Kehoe Law Firm, P.C. and Holzer & Holzer, LLC have announced investigations into Capricor Therapeutics regarding securities.
When is the next regulatory milestone for Capricor?
An FDA decision regarding the company's therapy is expected in August 2026.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
FDA recalls levothyroxine sodium tablets. Here's what to know
The FDA has announced a nationwide recall for levothyroxine sodium tablets, impacting patients who rely on the thyroid medication.
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics stock has declined following mixed topline results from the Phase 2 ZEPHYR trial of its schizophrenia candidate, ML-007C-MA.
Nvidia drops nearly 5%, leading chip stocks lower amid renewed worries of circular financing
Nvidia shares slipped nearly 5% as market sentiment shifts due to concerns over circular financing and changing data center dynamics.
Apple Stock Hits Record High Before Fiscal Q3 Earnings
Apple stock has reached a record high as investors and analysts prepare for the company's fiscal Q3 2026 earnings report.
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has initiated a nationwide recall of levothyroxine sodium tablets, citing the medication as a subpotent drug.
5 Things to Know Before the Stock Market Opens on Monday
Investors are monitoring pre-market activity and sector-specific indicators as markets prepare for the Monday morning opening.